



## ASX Release

### Tranche 2 Capital Raising Complete and Appendix 3B

Melbourne, Australia - (June, 23 2016) – Clinical-stage oncology company Prescient Therapeutics Ltd (ASX: PTX) is pleased to announce that pursuant to the Company's ASX announcement of 18 May 2016 and shareholder approval received at its general meeting of shareholders held on 22 June 2016, a total of 58,333,336 fully paid ordinary shares have been issued with an issue price of \$0.09 (9 cents) per share to professional and sophisticated investors.

An Appendix 3B relating to the share issue is attached to this announcement.

#### Section 708A Notice

This notice is given by Prescient Therapeutics Limited (**Company**) under Section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**) that:

- (a) the Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) the Company is providing this notice under paragraph 5(e) of section 708A of the Corporations Act;
- (c) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:
  - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - (ii) section 674 of the Corporations Act as it applies to the Company; and
- (d) as at the date of this announcement, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act.

**ENDS**

#### **About Prescient Therapeutics Limited (PTX)**

PTX is a clinical stage oncology company developing novel compounds that show promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

PTX's lead drug candidate PTX-200 inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound is now the focus of three current clinical trials.



The first trial is a Phase Ib/II trial evaluating PTX-200 as a new therapy for relapse and refractory Acute Myeloid Leukemia, being conducted at Florida's H. Lee Moffitt Cancer Center (Moffitt) and Yale Cancer Center (Yale) in New Haven, Connecticut under the leadership of Principal Investigator Professor Jeffrey Lancet, MD.

PTX is also conducting a Phase Ib/II study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York and the Moffitt. The third trial is a Phase Ib/II trial of PTX-200 in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at the Moffitt.

PTX's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase I trial in advanced solid tumors.

### **Further Inquiries:**

**Steven Yatomi-Clarke**  
CEO & Managing Director  
+61 417 601 440

**Paul Hopper**  
Executive Director  
+61 406 671 515

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

Prescient Therapeutics Limited

ABN

56 006 569 106

We (the entity) give ASX the following information.

### Part 1 - All issues

*You must complete the relevant sections (attach sheets if there is not enough space).*

- |   |  |                            |
|---|--|----------------------------|
| 1 | +Class of +securities issued or to be issued   | Fully paid ordinary shares |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued  | 58,333,336                 |
| 3 | Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | Fully paid ordinary shares |

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

|    |   |   |
|----|---|---|
| 4  | Do the <sup>+</sup> securities rank equally in all respects from the date of allotment with an existing <sup>+</sup> class of quoted <sup>+</sup> securities?   | Yes – Fully paid ordinary shares  |
|    | <p>If the additional securities do not rank equally, please state:</p> <ul style="list-style-type: none"> <li>• the date from which they do</li> <li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul> |   |
| 5  | Issue price or consideration  | \$0.09 (9 cents)  |
| 6  | Purpose of the issue<br>(If issued as consideration for the acquisition of assets, clearly identify those assets)   | Tranche 2 share issue in accordance with the Company's ASX announcement dated 18 May 2016 to progress the Company's clinical programs, including additional drug manufacture and clinical trial management, funding the costs associated with the capital raising and for working capital purposes. |
| 6a | <p>Is the entity an <sup>+</sup>eligible entity that has obtained security holder approval under rule 7.1A?</p> <p>If Yes, complete sections 6b – 6h <i>in relation to the <sup>+</sup>securities the subject of this Appendix 3B</i>, and comply with section 6i</p>   | Yes   |
| 6b | The date the security holder resolution under rule 7.1A was passed  | 4 November 2015   |
| 6c | Number of <sup>+</sup> securities issued without security holder approval under rule 7.1  | Nil   |
| 6d | Number of <sup>+</sup> securities issued with security holder approval under rule 7.1A  | Nil   |
| 6e | Number of <sup>+</sup> securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)   | 58,333,336 fully paid ordinary shares – 22 June 2016  |
| 6f | Number of securities issued under an exception in rule 7.2  | Nil   |

---

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

|    |  |  |  |
|----|--|--|--|
| 6g | If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation. | N/A  |  |
| 6h | If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements  | N/A  |  |
| 6i | Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements   | LR 7.1<br>LR 7.1A<br>Total   | 25,527,917<br><u>17,151,945</u><br>42,679,862  |
| 7  | Dates of entering +securities into uncertificated holdings or despatch of certificate  | 23 June 2016   |  |
| 8  | Number and +class of all +securities quoted on ASX ( <i>including</i> the securities in section 2 if applicable)   | Number<br>171,519,449  | +Class<br>Ordinary fully paid Shares   |
| 9  | Number and +class of all +securities not quoted on ASX ( <i>including</i> the securities in section 2 if applicable)   | 4,385,000<br><br>500,000<br><br>300,000<br><br>200,000<br><br>700,000<br><br>1,300,000 | Unlisted Options exercisable @ \$0.10 each, expiring on 12 October 2017.<br><br>Unlisted Options exercisable @ \$0.14 each, expiring on 11 December 2018.<br><br>Unlisted Options exercisable @ \$0.092 each, expiring on 6 May 2018<br><br>Unlisted Options exercisable @ \$0.06 each, expiring on 20 October 2020<br><br>Unlisted Options exercisable @ \$0.085 each, expiring on 4 November 2018<br><br>Unlisted options exercisable @ \$0.10 each, expiring 10 December 2018 |
| 10 | Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)   | N/A  |  |

+ See chapter 19 for defined terms.

## Part 2 - Bonus issue or pro rata issue

- |    |   |     |
|----|---|-----|
| 11 | Is security holder approval required?   | N/A |
| 12 | Is the issue renounceable or non-renounceable?  | N/A |
| 13 | Ratio in which the +securities will be offered  | N/A |
| 14 | +Class of +securities to which the offer relates  | N/A |
| 15 | +Record date to determine entitlements  | N/A |
| 16 | Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?  | N/A |
| 17 | Policy for deciding entitlements in relation to fractions   | N/A |
| 18 | Names of countries in which the entity has +security holders who will not be sent new issue documents<br><br><small>Note: Security holders must be told how their entitlements are to be dealt with.<br/>Cross reference: rule 7.7.</small> | N/A |
| 19 | Closing date for receipt of acceptances or renunciations  | N/A |
| 20 | Names of any underwriters   | N/A |
| 21 | Amount of any underwriting fee or commission  | N/A |
| 22 | Names of any brokers to the issue   | N/A |
| 23 | Fee or commission payable to the broker to the issue  | N/A |

---

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

|    |   |     |
|----|---|-----|
| 24 | Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders   | N/A |
| 25 | If the issue is contingent on +security holders' approval, the date of the meeting  | N/A |
| 26 | Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled  | N/A |
| 27 | If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders | N/A |
| 28 | Date rights trading will begin (if applicable)  | N/A |
| 29 | Date rights trading will end (if applicable)  | N/A |
| 30 | How do +security holders sell their entitlements <i>in full</i> through a broker?   | N/A |
| 31 | How do +security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?  | N/A |
| 32 | How do +security holders dispose of their entitlements (except by sale through a broker)?   | N/A |
| 33 | +Despatch date  | N/A |

---

+ See chapter 19 for defined terms.

## Part 3 - Quotation of securities

*You need only complete this section if you are applying for quotation of securities*

34 Type of securities  
(tick one)

(a)  Securities described in Part 1

(b)  All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

*Tick to indicate you are providing the information or documents*

35  If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

36  If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories  
1 - 1,000  
1,001 - 5,000  
5,001 - 10,000  
10,001 - 100,000  
100,001 and over

37  A copy of any trust deed for the additional +securities

### Entities that have ticked box 34(b)

38 Number of securities for which +quotation is sought

39 Class of +securities for which quotation is sought

---

+ See chapter 19 for defined terms.



|    |  |     |
|----|--|-----|
| 40 | <p>Do the <sup>+</sup>securities rank equally in all respects from the date of allotment with an existing <sup>+</sup>class of quoted <sup>+</sup>securities?</p> <p>If the additional securities do not rank equally, please state:</p> <ol style="list-style-type: none"> <li>1. the date from which they do</li> <li>2. the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>3. the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ol> | N/A |
|----|--|-----|

|    |  |     |
|----|--|-----|
| 41 | <p>Reason for request for quotation now</p> <p>Example: In the case of restricted securities, end of restriction period</p> <p>(if issued upon conversion of another security, clearly identify that other security)</p> | N/A |
|----|--|-----|

| 42     | <p>Number and <sup>+</sup>class of all <sup>+</sup>securities quoted on ASX (<i>including</i> the securities in clause 38)</p> | <table border="1" style="width: 100%;"> <thead> <tr> <th style="width: 50%;">Number</th> <th style="width: 50%;"><sup>+</sup>Class</th> </tr> </thead> <tbody> <tr> <td style="height: 40px;"></td> <td></td> </tr> </tbody> </table> | Number | <sup>+</sup> Class |  |  |
|--------|--|---|--------|--------------------|--|--|
| Number | <sup>+</sup> Class   |   |        |                    |  |  |
|        |  |   |        |                    |  |  |

<sup>+</sup> See chapter 19 for defined terms.



## Appendix 3B – Annexure 1

### Calculation of placement capacity under rule 7.1 and rule 7.1A for +eligible entities

Introduced 01/08/12

#### Part 1

| <b>Rule 7.1 – Issues exceeding 15% of capital</b>  |  |
|--|--|
| <b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>  |  |
| <b>Insert</b> number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue   | 57,248,221   |
| <p><b>Add</b> the following:</p> <ul style="list-style-type: none"> <li>• Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>• Number of fully paid ordinary securities issued in that 12 month period with shareholder approval</li> <li>• Number of partly paid ordinary securities that became fully paid in that 12 month period</li> </ul> <p><i>Note:</i></p> <ul style="list-style-type: none"> <li>• <i>Include only ordinary securities here – other classes of equity securities cannot be added</i></li> <li>• <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul> | <p>17,174,368 – 23 November 2015</p> <p>19,319,076 – 30 November 2015</p> <p>19,444,448 – 24 May 2016</p> <p>58,333,335 – 23 June 2016</p> |
| <b>Subtract</b> the number of fully paid ordinary securities cancelled during that 12 month period   | -  |
| <b>“A”</b>   | 171,519,448  |

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

| <b>Step 2: Calculate 15% of “A”</b>   |  |
|---|--|
| “B”   | 0.15<br><i>[Note: this value cannot be changed]</i>                                  |
| <b>Multiply</b> “A” by 0.15   | 25,727,917   |
| <b>Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used</b>  |  |
| <p><b>Insert</b> number of equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> <li>• Under an exception in rule 7.2</li> <li>• Under rule 7.1A</li> <li>• With security holder approval under rule 7.1 or rule 7.4</li> </ul> <p><i>Note:</i></p> <ul style="list-style-type: none"> <li>• <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i></li> <li>• <i>Include here (if applicable ) the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul> | 200,000 – 23 November 2015   |
| “C”   | <b>200,000</b>   |
| <b>Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1</b>   |  |
| “A” x 0.15<br><i>Note: number must be same as shown in Step 2</i>   | 25,727,917   |
| <b>Subtract</b> “C”<br><i>Note: number must be same as shown in Step 3</i>  | 200,000  |
| <b>Total</b> [“A” x 0.15] – “C”   | 25,527,917<br><i>[Note: this is the remaining placement capacity under rule 7.1]</i> |

+ See chapter 19 for defined terms.

## Part 2

| <b>Rule 7.1A – Additional placement capacity for eligible entities</b>  |   |
|---|---|
| <b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>   |   |
| <b>“A”</b><br><i>Note: number must be same as shown in Step 1 of Part 1</i>   | 171,519,448                                       |
| <b>Step 2: Calculate 10% of “A”</b>   |   |
| <b>“D”</b>  | 0.10<br><i>Note: this value cannot be changed</i> |
| <b>Multiply “A” by 0.10</b>   | 17,151,945  |
| <b>Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used</b>   |   |
| <b>Insert</b> number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A<br><br><b>Notes:</b> <ul style="list-style-type: none"> <li>• <i>This applies to equity securities – not just ordinary securities</i></li> <li>• <i>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul> | -   |
| <b>“E”</b>  | 17,151,945  |

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

| <b>Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A</b> |   |
|--|---|
| "A" x 0.10<br><i>Note: number must be same as shown in Step 2</i>                                      | 17,151,945  |
| <b>Subtract "E"</b><br><i>Note: number must be same as shown in Step 3</i>                             | -   |
| <b>Total</b> ["A" x 0.10] – "E"  | 17,151,945<br><i>[Note: this is the remaining placement capacity under rule 7.1A]</i> |

---

+ See chapter 19 for defined terms.